Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 165352, 7 pages
Research Article

Decreasing Quality of the New Generations of Anti-Müllerian Hormone Assays

1INVICTA Fertility and Reproductive Centre, 80-850 Gdansk, Poland
2Department of Nursing, Medical University, 80-952 Gdansk, Poland
3Department of Obstetrics and Gynecology, Faculty of Medical Sciences, Varmia and Masuria University, 10-561 Olsztyn, Poland
4INVICTA Fertility and Reproductive Centre, 00-019 Warsaw, Poland
5Department of Photophysics, IFFM Polish Academy of Sciences, 80-952 Gdansk, Poland
6Department of Obstetrics and Gynecology, The Medical Center of Postgraduate Education, 00-416 Warsaw, Poland
7Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, 10-747 Olsztyn, Poland

Received 25 November 2013; Accepted 31 January 2014; Published 11 March 2014

Academic Editor: Gottfried E. Konecny

Copyright © 2014 Krzysztof Lukaszuk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Anti-Müllerian hormone (AMH) measurements are widely used to optimize the stimulation protocols. First generation AMH kits correlated well with ovarian reserve and response to stimulation. In the present study we aimed to asses if the new generation kits share the same accurate correlations. Retrospective data were collected from 8323 blood samples. For comparison we used Immunotech I generation kit (ImI 4035 samples), Beckman Coulter II generation kit RUO (BCII RUO 3449, samples) and Beckman Coulter II generation kit with IVD certificate (BCII IVD 839 samples). We compared average AMH concentrations measured with different kits, as well as correlation between kits. We also compared average AMH concentrations in sera collected on different cycle days and samples of different quality of preservation. AMH serum concentrations differed for each kit, ranging 4.4 ± 4.12 (mean ± SD) for the ImI, 2.68 ± 3.15 for the BCII RUO, and 1.64 ± 2.85 for BCII IVD. The mean differences from an adjusted regression model were −48.7%, −40%, and −69.2%, respectively. In conclusion, the changes of the BC AMH kits are unpredictable; however, the improvement of them is still possible. It would be very dangerous to use elaborated stimulation protocol (based on the Ist generation AMH results) with the results from the IInd generation assays.